Literature DB >> 27780725

In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations.

Federica Ferrari1, Maria Camilla Cerlesi1, Davide Malfacini1, Laila Asth2, Elaine C Gavioli2, Blair V Journigan3, Uma Gayathri Kamakolanu3, Michael E Meyer3, Dennis Yasuda3, Willma E Polgar4, Anna Rizzi1, Remo Guerrini5, Chiara Ruzza1, Nurulain T Zaveri3, Girolamo Calo6.   

Abstract

Nociceptin/Orphanin FQ (N/OFQ) regulates several biological functions via selective activation of the N/OFQ receptor (NOP). In this study novel nonpeptide NOP ligands were characterized in vitro in receptor binding and [35S]GTPγS stimulated binding in membranes of cells expressing human NOP and classical opioid receptors, calcium mobilization assay in cells coexpressing the receptors and chimeric G proteins, bioluminescence resonance energy transfer (BRET) based assay for studying NOP receptor interaction with G protein and arrestin, the electrically stimulated mouse vas deferens and the mouse colon bioassays. The action of the AT compounds were compared with standard NOP agonists (N/OFQ and Ro 65-6570) and the NOP selective antagonist SB-612111. AT compounds displayed high NOP affinity and behaved as NOP agonists in all the functional assays consistently showing the following rank order of potency AT-127≥AT-090≥AT-035>AT-004= AT-001. AT compounds behaved as NOP full agonists in the calcium mobilization and mouse colon assays and as partial agonists in the [35S]GTPγS and BRET assays. Interestingly AT-090 and AT-127, contrary to standard nonpeptide agonists that display G protein biased agonism, behaved as an unbiased agonists. AT-090 and AT-127 displayed higher NOP selectivity than Ro 65-6570 at native mouse receptors. AT-090 and AT-127 might be useful pharmacological tools for investigating the therapeutic potential of NOP partial agonists. Copyright Â
© 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bioluminescence resonance energy transfer; Calcium mobilization and mouse colon vas deferens and assays; NOP and classical opioid receptors; Receptor and [(35)S]GTPγS binding

Mesh:

Substances:

Year:  2016        PMID: 27780725      PMCID: PMC5555400          DOI: 10.1016/j.ejphar.2016.10.025

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  37 in total

1.  Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson's disease.

Authors:  Matteo Marti; Silvio Sarubbo; Francesco Latini; Michele Cavallo; Roberto Eleopra; Sara Biguzzi; Christian Lettieri; Carlo Conti; Michele Simonato; Silvia Zucchini; Rocco Quatrale; Mariachiara Sensi; Sanzio Candeletti; Patrizia Romualdi; Michele Morari
Journal:  Mov Disord       Date:  2010-08-15       Impact factor: 10.338

Review 2.  Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.

Authors:  W Schröder; D G Lambert; M C Ko; T Koch
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

3.  A selective small molecule NOP (ORL-1 receptor) partial agonist for the treatment of anxiety.

Authors:  Tina Morgan Ross; Kathleen Battista; Gilles C Bignan; Doug E Brenneman; Peter J Connolly; Jingchun Liu; Steven A Middleton; Michael Orsini; Allen B Reitz; Dan I Rosenthal; Malcolm K Scott; Anil H Vaidya
Journal:  Bioorg Med Chem Lett       Date:  2014-12-17       Impact factor: 2.823

4.  Effects of Ro 64-6198 in nociceptin/orphanin FQ-sensitive isolated tissues.

Authors:  D Rizzi; R Bigoni; A Rizzi; F Jenck; J Wichmann; R Guerrini; D Regoli; G Calo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2001-05       Impact factor: 3.000

5.  Chimeric G proteins in fluorimetric calcium assays: experience with opioid receptors.

Authors:  Valeria Camarda; Girolamo Calo'
Journal:  Methods Mol Biol       Date:  2013

Review 6.  Practical guide for calculating and representing biased signaling by GPCR ligands: A stepwise approach.

Authors:  Karim Nagi; Graciela Pineyro
Journal:  Methods       Date:  2015-09-11       Impact factor: 3.608

7.  Novel Synthesis and Pharmacological Characterization of NOP Receptor Agonist 8-[(1S,3aS)-2,3,3a,4,5,6-Hexahydro-1H-phenalen-1-yl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (Ro 64-6198).

Authors:  Steven D Chang; Lawrence E Brieaddy; Joseph D Harvey; Anita H Lewin; S Wayne Mascarella; Herbert H Seltzman; P Anantha Reddy; Ann M Decker; Charles J McElhinny; Desong Zhong; Elisha E Peterson; Hernán A Navarro; Michael R Bruchas; F Ivy Carroll
Journal:  ACS Chem Neurosci       Date:  2015-09-30       Impact factor: 4.418

Review 8.  The pharmacology of Ro 64-6198, a systemically active, nonpeptide NOP receptor (opiate receptor-like 1, ORL-1) agonist with diverse preclinical therapeutic activity.

Authors:  James R Shoblock
Journal:  CNS Drug Rev       Date:  2007

9.  Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.

Authors:  J R Traynor; S R Nahorski
Journal:  Mol Pharmacol       Date:  1995-04       Impact factor: 4.436

10.  The Importance of Ligand-Receptor Conformational Pairs in Stabilization: Spotlight on the N/OFQ G Protein-Coupled Receptor.

Authors:  Rebecca L Miller; Aaron A Thompson; Claudio Trapella; Remo Guerrini; Davide Malfacini; Nilkanth Patel; Gye Won Han; Vadim Cherezov; Girolamo Caló; Vsevolod Katritch; Raymond C Stevens
Journal:  Structure       Date:  2015-10-29       Impact factor: 5.006

View more
  7 in total

1.  Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists.

Authors:  Ludovico Arcuri; Salvatore Novello; Martina Frassineti; Daniela Mercatelli; Clarissa Anna Pisanò; Ilaria Morella; Stefania Fasano; Blair V Journigan; Michael E Meyer; Willma E Polgar; Riccardo Brambilla; Nurulain T Zaveri; Michele Morari
Journal:  Br J Pharmacol       Date:  2018-01-31       Impact factor: 8.739

2.  Agonist-selective NOP receptor phosphorylation correlates in vitro and in vivo and reveals differential post-activation signaling by chemically diverse agonists.

Authors:  Anika Mann; Lionel Moulédous; Carine Froment; Patrick R O'Neill; Pooja Dasgupta; Thomas Günther; Gloria Brunori; Brigitte L Kieffer; Lawrence Toll; Michael R Bruchas; Nurulain T Zaveri; Stefan Schulz
Journal:  Sci Signal       Date:  2019-03-26       Impact factor: 8.192

3.  Cardiovascular and renal effects of novel nonpeptide nociceptin opioid peptide receptor agonists.

Authors:  Ian B Denys; Juan Gao; Jane C Sutphen; Nurulain T Zaveri; Daniel R Kapusta
Journal:  Br J Pharmacol       Date:  2021-12-12       Impact factor: 8.739

Review 4.  Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors.

Authors:  Jolien De Neve; Thomas M A Barlow; Dirk Tourwé; Frédéric Bihel; Frédéric Simonin; Steven Ballet
Journal:  RSC Med Chem       Date:  2021-04-21

5.  Differential In Vitro Pharmacological Profiles of Structurally Diverse Nociceptin Receptor Agonists in Activating G Protein and Beta-Arrestin Signaling at the Human Nociceptin Opioid Receptor.

Authors:  James J Lu; Willma E Polgar; Anika Mann; Pooja Dasgupta; Stefan Schulz; Nurulain T Zaveri
Journal:  Mol Pharmacol       Date:  2021-05-06       Impact factor: 4.054

6.  In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403.

Authors:  Federica Ferrari; Davide Malfacini; Blair V Journigan; Mark F Bird; Claudio Trapella; Remo Guerrini; David G Lambert; Girolamo Calo'; Nurulain T Zaveri
Journal:  Pharmacol Res Perspect       Date:  2017-08

7.  NOP receptor pharmacological profile - A dynamic mass redistribution study.

Authors:  Davide Malfacini; Katharina Simon; Claudio Trapella; Remo Guerrini; Nurulain T Zaveri; Evi Kostenis; Girolamo Calo'
Journal:  PLoS One       Date:  2018-08-30       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.